Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 4/20 | 0.63 |
| ▸ | PTPRC | P08575 | 1/20 | 0.60 |
| ▸ | BCL2 | P10415 | 3/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PPOX | P50336 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29914626 | 1.00 | S100A4 (0.63) | S100A4PTPRCBCL2MCL1HSP90AA1 | |
| SCHEMBL24730389 | 0.96 | BCL2 (0.57) | S100A4PTPRCBCL2MCL1HSP90AA1 | |
| SCHEMBL6884062 | 0.96 | BCL2 (0.62) | S100A4PTPRCBCL2MCL1HSP90AA1 | |
| SCHEMBL29018327 | 0.93 | S100A4 (0.72) | S100A4PTPRCBCL2MCL1HSP90AA1 | |
| SCHEMBL1758285 | 0.92 | S100A4 (0.61) | S100A4PTPRCBCL2MCL1HSP90AA1 | |
| SCHEMBL19767754 | 0.88 | S100A4 (0.81) | S100A4PTPRCBCL2MCL1ESR1 | |
| SCHEMBL16659000 | 0.83 | S100A4 (0.90) | S100A4PTPRCBCL2MCL1HSP90AA1 | |
| SCHEMBL4319897 | 0.83 | S100A4 (0.71) | S100A4HSP90AA1ITGA1PPOXESR1 | |
| SCHEMBL762135 | 0.83 | S100A4 (0.80) | S100A4PTPRCBCL2MCL1NPC1 | |
| SCHEMBL39700 | 0.83 | S100A4 (0.90) | S100A4PTPRCBCL2MCL1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| CN-114929676-B | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | LILAC THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4470538-A2 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240091200-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | Lilac Therapeutics, Inc. | 2024-03-21 | — | — | US | disclosed |
| CN-116730799-B | OLED compound containing spirofluorene structure and preparation method thereof | 西安欧得光电材料有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116730799-A | OLED compound containing spirofluorene structure and preparation method thereof | 西安欧得光电材料有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4051667-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114929676-A | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-111217715-B | Diarylamine substituted spirobifluorene compound and application thereof in OLED device | 常州强力电子新材料股份有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-20210128532-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| WO-2021086874-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | GyanRx Sciences, Inc. (US) | 2021-05-06 | — | — | WO | disclosed |
| CN-111217715-A | Diarylamine substituted spirobifluorene compound and application thereof in OLED device | 常州强力电子新材料股份有限公司 | 2020-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091200-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | UGDH, PGD, PNPO | S100A4 2794/4885PTPRC 1050/4885BCL2 4416/4885 |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | S100A4 2794/4885PTPRC 1050/4885BCL2 4416/4885 |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | S100A4 2794/4885PTPRC 1050/4885BCL2 4416/4885 |
| US-20210128532-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | UGDH, PGD, PNPO | S100A4 2794/4885PTPRC 1050/4885BCL2 4416/4885 |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | GLS, DUOX1, HAO1 | S100A4 3751/4885PTPRC 2755/4885BCL2 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.